Bruce Cozadd

Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?

Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?

Jazz Pharma Q1 FY23 Revenue Grows 10% YoY, What About Net Income?

Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?

Jazz Pharma Q1 FY23 Revenue Grows 10% YoY, What About Net Income?

Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook

Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?

Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook

Jazz Pharmaceuticals Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics, What's Next?

Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY

Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma

Bruce Cozadd Recent News

Jazz Pharmaceuticals Announces Full Year And 4Q 2021 Financial Results

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022.

Jazz Pharmaceuticals Q2 Revenue Jumps 34% To $751.8M With $109.5M Epidiolex Net Sales, Reaffirms Its 2021 Guidance Of $3.02B

Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) reported its financial results on Tuesday for the second quarter of 2021 with total revenue of $751.81 million, up by 34% from $562.43 million in the

Jazz Pharmaceuticals Closes On Acquisition Of GW Pharma, Adds CBD Drug Epidiolex To Portfolio

The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH).

Celator Surges 70% After Acquisition Announcement By Jazz Pharmaceuticals